Notice: Trading of PainReform halted at 09:40 AM EST due to "LULD pause". PainReform (PRFX) News Today $3.15 -1.01 (-24.28%) (As of 12:20 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period PainReform Ltd: PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialNovember 21 at 3:56 AM | finanznachrichten.dePainReform Stock Is Soaring Tuesday: What's Going On?November 21 at 3:56 AM | benzinga.comPainReform’s PRF-110 Shows Promise in Initial Trial ResultsNovember 21 at 3:56 AM | markets.businessinsider.comPainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialNovember 20 at 8:30 AM | globenewswire.comPainReform Announces 1-for-4 Reverse Share SplitNovember 18 at 8:47 PM | markets.businessinsider.comPainReform Faces Nasdaq Compliance Challenge Amid Drug DevelopmentNovember 9, 2024 | markets.businessinsider.comPainReform receives noncompliance notification from NasdaqNovember 7, 2024 | markets.businessinsider.comPainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNovember 7, 2024 | markets.businessinsider.comPainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementNovember 7, 2024 | globenewswire.comMaxim Group Downgrades PainReform (PRFX)October 25, 2024 | msn.comPainReform cut to Hold at Maxim amid ‘changed’ market dynamicsOctober 25, 2024 | finance.yahoo.comPainReform Shares Are Trading Lower Today: What's Going OnSeptember 11, 2024 | msn.comPainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110September 11, 2024 | globenewswire.comPainReform Announces Exercise of Warrants for $1.58 Million Gross ProceedsSeptember 10, 2024 | globenewswire.comPainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresAugust 21, 2024 | finance.yahoo.comPainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy StudyAugust 20, 2024 | globenewswire.comBuy Rating Justified by PainReform’s Promising PRF-110 with Competitive Edge and Positive Clinical DataAugust 17, 2024 | markets.businessinsider.comPainReform Provides Business Update for the Second Quarter of 2024August 15, 2024 | finance.yahoo.comPainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic EffectsAugust 12, 2024 | finance.yahoo.comBuy Rating Affirmed for PainReform as PRF-110 Shows Promise in Clinical DevelopmentsAugust 9, 2024 | markets.businessinsider.comPainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher DosesAugust 7, 2024 | globenewswire.comPainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110August 5, 2024 | finance.yahoo.comPainReform’s New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureAugust 1, 2024 | markets.businessinsider.comPainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureAugust 1, 2024 | globenewswire.comPainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and TestingJuly 24, 2024 | finance.yahoo.comPainReform Announces Receipt of Nasdaq Minimum Bid Price NotificationMay 31, 2024 | globenewswire.comPainReform Ltd: PainReform Provides Business Update for the First Quarter of 2024May 16, 2024 | finanznachrichten.dePRFX Stock Earnings: PainReform Misses EPS for Q1 2024May 15, 2024 | msn.comPainReform Provides Business Update for the First Quarter of 2024May 15, 2024 | globenewswire.comPainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.comMay 8, 2024 | globenewswire.comPainReform Announces Closing of $4 Million Public OfferingApril 18, 2024 | globenewswire.comPainReform Announces Pricing of $4 Million Public OfferingApril 16, 2024 | finance.yahoo.comEXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing ConditionsApril 9, 2024 | msn.comPainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 9, 2024 | finance.yahoo.comPainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 9, 2024 | globenewswire.comUK watchdog says Theramex-Viatris deal raises competition concernsApril 4, 2024 | finance.yahoo.comBuy Rating Affirmed for PainReform as PRF-110 Shows Promise in Non-Opioid Pain Management MarketApril 4, 2024 | markets.businessinsider.comEXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain DrugApril 2, 2024 | finance.yahoo.comPainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyApril 2, 2024 | globenewswire.comBuy Rating for PainReform’s PRF-110: Promising Non-Opioid Pain Solution Amidst Opioid CrisisMarch 7, 2024 | markets.businessinsider.comPainReform Provides Year-End Business UpdateMarch 1, 2024 | globenewswire.comPainReform to Present at the Microcap Conference in Atlantic CityJanuary 22, 2024 | finance.yahoo.comPainReform files to sell 968,545 ordinary shares for holdersJanuary 12, 2024 | msn.comBuy Rating for PainReform’s PRF-110: Superior Spreadability Signaling Market AdvantageJanuary 5, 2024 | markets.businessinsider.comPainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain ReliefJanuary 3, 2024 | finance.yahoo.comPainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross ProceedsDecember 26, 2023 | finance.yahoo.comPainReform Stock (NASDAQ:PRFX) Dividends: History, Yield and DatesDecember 19, 2023 | benzinga.comPainReform Ltd: PainReform Provides Business Update for the Third Quarter of 2023November 19, 2023 | finanznachrichten.deAnalysts Offer Insights on Healthcare Companies: PainReform (PRFX) and Tenet Healthcare (THC)November 18, 2023 | markets.businessinsider.comPainReform Provides Business Update for the Third Quarter of 2023November 15, 2023 | finance.yahoo.com Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here PRFX Media Mentions By Week PRFX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRFX News Sentiment▼0.300.47▲Average Medical News Sentiment PRFX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRFX Articles This Week▼81▲PRFX Articles Average Week Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BCLI News Today CANF News Today BIOR News Today ABVC News Today EVOK News Today EDSA News Today GTBP News Today ADIL News Today EYEN News Today RNAZ News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRFX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRFX Stock Alerts